Payment overview · 2025
General Payments
$238.22
11 reported records · 5 companies
Healthcare provider profile · identity verified
Syed Naseeruddin, MD
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · SAINT CLOUD, FL · NPI 1235187527
Verified facts
What the public records show
CMS Open Payments records show Syed Naseeruddin, MD received $238.22 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.64 | 32.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.79 | 20.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.58 | 19.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.75 | 15.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.46 | 12.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.22 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.98 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.79 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.58 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.58 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 183 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
134 | 44 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
183 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1025 | 344 |
| Gabapentin | Gabapentin | 781 | 257 |
| Amlodipine Besylate | Amlodipine Besylate | 719 | 249 |
| Losartan Potassium | Losartan Potassium | 555 | 177 |
| Lisinopril | Lisinopril | 486 | 158 |
| Metformin Hcl | Metformin Hcl | 416 | 150 |
| Fluticasone Propionate | Fluticasone Propionate | 368 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 301 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 298 | 103 |
| Glipizide | Glipizide | 298 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 93 |
| Carvedilol | Carvedilol | 237 | 92 |
| Omeprazole | Omeprazole | 231 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 82 |
| Ozempic | Semaglutide | 183 | 41 |
| Trazodone Hcl | Trazodone Hcl | 181 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 177 | 55 |
| Montelukast Sodium | Montelukast Sodium | 174 | 60 |
| Allopurinol | Allopurinol | 154 | 50 |
| Furosemide | Furosemide | 154 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 153 | 63 |
| Meloxicam | Meloxicam | 153 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 68 |
| Alendronate Sodium | Alendronate Sodium | 148 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 51 |
| Farxiga | Dapagliflozin Propanediol | 134 | 44 |
| Famotidine | Famotidine | 128 | 54 |
| Jardiance | Empagliflozin | 128 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 54 |
| Donepezil Hcl | Donepezil Hcl | 120 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 37 |
| Eliquis | Apixaban | 112 | 42 |
| Methocarbamol | Methocarbamol | 105 | 41 |
| Tramadol Hcl | Tramadol Hcl | 103 | 27 |
| Simvastatin | Simvastatin | 100 | 39 |
| Calcitriol | Calcitriol | 98 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 30 |
| Mirtazapine | Mirtazapine | 95 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 44 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 90 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 84 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 39 |
| Azithromycin | Azithromycin | 81 | 73 |
| Ezetimibe | Ezetimibe | 80 | 23 |
| Pregabalin | Pregabalin | 80 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 29 |
| Ibuprofen | Ibuprofen | 75 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 32 |
| Prednisone | Prednisone | 74 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 23 |
| Spironolactone | Spironolactone | 70 | 34 |
| Glimepiride | Glimepiride | 68 | 21 |
| Sertraline Hcl | Sertraline Hcl | 65 | 17 |
| Clonidine Hcl | Clonidine Hcl | 64 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 29 |
| Finasteride | Finasteride | 63 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 15 |
| Meclizine Hcl | Meclizine Hcl | 61 | 26 |
| Januvia | Sitagliptin Phosphate | 59 | 19 |
| Potassium Chloride | Potassium Chloride | 59 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 21 |
| Baclofen | Baclofen | 56 | 19 |
| Breyna | Budesonide/Formoterol Fumarate | 55 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 45 |
| Topiramate | Topiramate | 51 | 16 |
| Torsemide | Torsemide | 51 | 20 |
| Atenolol | Atenolol | 49 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 16 |
| Latanoprost | Latanoprost | 48 | 11 |
| Lactulose | Lactulose | 42 | 19 |
| Methylprednisolone | Methylprednisolone | 42 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Valsartan | Valsartan | 41 | 12 |
| Labetalol Hcl | Labetalol Hcl | 40 | 13 |
| Nifedipine Er | Nifedipine | 39 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 12 |
| Novolog Flexpen | Insulin Aspart | 36 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | 12 |
| Bumetanide | Bumetanide | 35 | 13 |
| Levetiracetam | Levetiracetam | 34 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Memantine Hcl | Memantine Hcl | 31 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 13 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | 11 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 15 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 20 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Indomethacin | Indomethacin | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 11 |
| Cephalexin | Cephalexin | 18 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.22 · 11 records | PFIZER INC. | AIRSUPRA, JARDIANCE, Kerendia, Ozempic, Rybelsus, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error